PLx Pharma Proposes “GI-Safer” OTC Aspirin In New Drug Application
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm files a rare new drug application for an OTC product, a formulation of aspirin and phosphatidylcholine designed to be more tolerable to the gastrointestinal tract. The involvement of OTC veterans Peter Mann and Michael Valentino on PLx’s board suggests strong market potential.
You may also be interested in...
Prestige Brands Makes "Seismic Shift" To OTC With Blacksmith Acquisition
On the eve of Blacksmith Brands' one-year anniversary, co-founder and CEO Peter Mann fulfills his promise to cash in on the startup in a $190 million sale to Prestige Brands Holdings, which Mann also helped launch
FDA Expands Acetaminophen, NSAID Labeling Beyond Tentative Final Rule
FDA's final rule for OTC products containing acetaminophen or nonsteroidal anti-inflammatory drugs requires warnings and revisions that go beyond changes the agency proposed in a 2006 tentative final rule
L’Oréal’s Anthelios SX Will Launch Following FDA Approval Of UVA Filter
L'Oréal will introduce Anthelios SX, the first product on the U.S. market containing a sun filter for short UVA wave protection, this fall, the company announced July 24